NRS 439B.640 - Manufacturer of essential diabetes drug that has undergone significant price increase to submit report.

NV Rev Stat § 439B.640 (2019) (N/A)
Copy with citation
Copy as parenthetical citation

On or before April 1 of a year in which a drug is included on the list compiled pursuant to subsection 2 of NRS 439B.630, the manufacturer of the drug shall submit to the Department a report describing the reasons for the increase in the wholesale acquisition cost of the drug described in that subsection. The report must include, without limitation:

1. A list of each factor that has contributed to the increase;

2. The percentage of the total increase that is attributable to each factor;

3. An explanation of the role of each factor in the increase; and

4. Any other information prescribed by regulation by the Department.

(Added to NRS by 2017, 4298)